Memokath-051 stent for ureteric obstruction: draft guidance
We are listening to your views on this Medical technologies guidance. Comments close 13 September 2022.
Search results
4 results
-
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]: appraisal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 16 November 2021.
-
Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin's lymphoma [ID1685]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 31 August 2022.
-
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma [ID3760]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 2 September 2022.